- Home
- EGY vs KMDA Comparison
EGY vs KMDA Comparison
Compare EGY & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EGY
- KMDA
- Stock Information
- Founded
- EGY 1985
- KMDA 1990
- Country
- EGY United States
- KMDA Israel
- Employees
- EGY N/A
- KMDA N/A
- Industry
- EGY Oil & Gas Production
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- EGY Energy
- KMDA Health Care
- Exchange
- EGY Nasdaq
- KMDA Nasdaq
- Market Cap
- EGY 340.3M
- KMDA 399.7M
- IPO Year
- EGY N/A
- KMDA N/A
- Fundamental
- Price
- EGY $3.84
- KMDA $7.20
- Analyst Decision
- EGY
- KMDA Strong Buy
- Analyst Count
- EGY 0
- KMDA 3
- Target Price
- EGY N/A
- KMDA $14.67
- AVG Volume (30 Days)
- EGY 1.1M
- KMDA 71.8K
- Earning Date
- EGY 08-05-2025
- KMDA 08-13-2025
- Dividend Yield
- EGY 6.53%
- KMDA 2.77%
- EPS Growth
- EGY N/A
- KMDA 31.21
- EPS
- EGY 0.56
- KMDA 0.28
- Revenue
- EGY $489,162,000.00
- KMDA $167,235,000.00
- Revenue This Year
- EGY N/A
- KMDA $14.51
- Revenue Next Year
- EGY $24.62
- KMDA $9.31
- P/E Ratio
- EGY $6.89
- KMDA $26.07
- Revenue Growth
- EGY 3.02
- KMDA 11.83
- 52 Week Low
- EGY $3.00
- KMDA $4.74
- 52 Week High
- EGY $7.43
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- EGY 64.80
- KMDA 65.83
- Support Level
- EGY $3.30
- KMDA $6.78
- Resistance Level
- EGY $4.04
- KMDA $7.09
- Average True Range (ATR)
- EGY 0.15
- KMDA 0.16
- MACD
- EGY 0.05
- KMDA 0.04
- Stochastic Oscillator
- EGY 81.66
- KMDA 98.48
About EGY VAALCO Energy Inc.
VAALCO Energy Inc is an independent energy company operating in the United States. It is principally engaged in the acquisition, exploration, development, and production of crude oil and natural gas. The company operates through geographical segments namely Gabon, Egypt, Canada, Equatorial Guinea, and Cote d'Ivoire. The company generates maximum revenue from the Gabon segment.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.